ArticleBioconjugate chemistry2014
Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination.
Article in Bioconjugate chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits.Nature communications · 2024Article
- Vinyl Sulfone-functionalized Acetalated Dextran Microparticles as a Subunit Broadly Acting Influenza Vaccine.The AAPS journal · 2023Article
- Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Emerging vaccine nanotechnology: From defense against infection to sniping cancer.Acta pharmaceutica Sinica. B · 2022Review
- DNA-Directed Patterning for Versatile Validation and Characterization of a Lipid-Based Nanoparticle Model of SARS-CoV-2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.Scientific reports · 2021Article
- Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health.Nature nanotechnology · 2021Review
- Crosslinked polymer nanocapsules for therapeutic, diagnostic, and theranostic applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Conjugation of Native-Like HIV-1 Envelope Trimers onto Liposomes Using EDC/Sulfo-NHS Chemistry: Requirements and Limitations.Pharmaceutics · 2020Article
- Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin.Journal of virology · 2020Article
- Strategies for inducing effective neutralizing antibody responses against HIV-1.Expert review of vaccines · 2019Review
- Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials.Pharmaceutics · 2019Review
- Review
- Unidirectional Presentation of Membrane Proteins in Nanoparticle-Supported Liposomes.Angewandte Chemie (International ed. in English) · 2019Article
- Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses.Nanomedicine : nanotechnology, biology, and medicine · 2019Article
- Nano-multilamellar lipid vesicles (NMVs) enhance protective antibody responses against Shiga toxin (Stx2a) produced by enterohemorrhagic Escherichia coli strains (EHEC).Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2019Article
- Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes.Scientific reports · 2018Article
- Bionanotechnology for vaccine design.Current opinion in biotechnology · 2018Review
- Quantitation and Stability of Protein Conjugation on Liposomes for Controlled Density of Surface Epitopes.Bioconjugate chemistry · 2018Article
- Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Immunization strategies that elicit antibodies capable of neutralizing diverse virus strains will likely be an important part of a successful vaccine against HIV. However, strategies to promote robust humoral responses against the native intact HIV envelope trimer structure are lacking. We recently developed chemically cross-linked lipid nanocapsules as carriers of molecular adjuvants and encapsulated or surface-displayed antigens, which promoted follicular helper T-cell responses and elicited high-avidity, durable antibody responses to a candidate malaria antigen. To apply this system to the delivery of HIV antigens, Env gp140 trimers with terminal his-tags (gp140T-his) were anchored to the surface of lipid nanocapsules via Ni-NTA-functionalized lipids. Initial experiments revealed that the large (409 kDa), heavily glycosylated trimers were capable of extracting fluid phase lipids from the membranes of nanocapsules. Thus, liquid-ordered and/or gel-phase lipid compositions were required to stably anchor trimers to the particle membranes. Trimer-loaded nanocapsules combined with the clinically relevant adjuvant monophosphoryl lipid A primed high-titer antibody responses in mice at antigen doses ranging from 5 μg to as low as 100 ng, whereas titers dropped more than 50-fold over the same dose range when soluble trimer was mixed with a strong oil-in-water adjuvant comparator. Nanocapsule immunization also broadened the number of distinct epitopes on the HIV trimer recognized by the antibody response. These results suggest that nanocapsules displaying HIV trimers in an oriented, multivalent presentation can promote key aspects of the humoral response against Env immunogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.